SHARE:
Real-World Evidence in the Cloud: How
Technology is Revealing the Big Picture in Pharma
6
performance records, and the details of doctors
working in a particular therapeutic field for insights
that accelerate clinical trial enrollment. While
traditionally these datasets have been too vast to
analyze manually, machine learning capabilities in
the cloud can potentially reveal which sites should
have access to patients in the active disease state
and how they performed in the past.
This is one of a fast-growing number of ways artificial
intelligence and machine learning are aiding RWE.
Another is in the improvement of natural language
processing services that can be used to find insights
and relationships within text. Companies can utilize
services, such as Amazon Comprehend, to analyze
notes and other unstructured assets, enabling the
mining of resources that were largely closed off
from researchers in the past, but potentially hold
critical insights.
Whatever the application of machine learning, the
approaches are built on access to data. Cloud-based
data lakes facilitate faster and more efficient insights
by bringing all the data into one place and storing
it in a way that supports the pooled analysis of data
assets from vastly different sources.
PREPARING FOR TOMORROW
Many of the trends identified in this paper are only
going in one direction. Datasets will continue to get
bigger and more complex. Payer demands for evidence
of real-world value will become more intense. The
abilities of artificial intelligence, machine learning,
and natural language processing will continue to
grow and evolve, enabling teams to complete tasks in
hours, not weeks. This will become the new normal
for pharma companies.
Now is the time to prepare for this new normal. RWE
is and will remain, a dynamic space defined by the
need to quickly ingest and analyze new datasets as
they become available. Executing these tasks will
yield insights that drive the development of safer,
more efficacious medicines and the smarter use of
existing therapies.
Companies can seize these opportunities by building
platforms that use AWS' cloud and services to simplify
and automate the collection and analysis of real-world
data. These forward-thinking companies will do more
than just gain an advantage today. They will equip
themselves to come out on top as RWE becomes a
critical pharma battleground in the years to come. l
For over 12 years, Amazon Web Services has been the world's most comprehensive and broadly adopted
cloud platform. AWS offers over 125 fully featured services for compute, storage, databases, networking,
analytics, machine learning and artificial intelligence (AI), Internet of Things(IoT), mobile, security, hybrid,
virtual and augmented reality (VR and AR), media, and application development, deployment, and
management from 54 Availability Zones (AZs) within 18 geographic regions and one Local Region around the
world, spanning the U.S., Australia, Brazil, Canada, China, France, Germany, India, Ireland, Japan, Korea,
Singapore, and the UK. AWS services are trusted by millions of active customers around the world—including
the fastest-growing startups, largest enterprises, and leading government agencies—to power their
infrastructure, make them more agile, and lower costs.
To learn more about AWS, visit https://aws.amazon.com/health
